Ensign Peak Advisors Inc Sells 24,170 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Ensign Peak Advisors Inc cut its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 50.2% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 24,002 shares of the medical equipment provider’s stock after selling 24,170 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Lantheus were worth $1,927,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of LNTH. UMB Bank n.a. increased its holdings in Lantheus by 161.4% in the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 247 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 208 shares during the last quarter. Fidelis Capital Partners LLC acquired a new position in shares of Lantheus in the first quarter valued at approximately $34,000. FinTrust Capital Advisors LLC raised its holdings in Lantheus by 53.6% in the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock valued at $41,000 after buying an additional 232 shares during the last quarter. Finally, Nkcfo LLC acquired a new stake in Lantheus during the 2nd quarter worth approximately $47,000. 99.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

LNTH has been the subject of several recent research reports. JMP Securities decreased their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research report on Thursday, August 1st. B. Riley raised their target price on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Truist Financial cut their target price on Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Leerink Partners increased their price target on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, July 11th. Finally, Redburn Atlantic began coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective on the stock. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $126.00.

Insider Activity at Lantheus

In other Lantheus news, Director Gary J. Pruden sold 12,530 shares of the stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total value of $1,190,851.20. Following the transaction, the director now owns 11,978 shares in the company, valued at $1,138,389.12. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Lantheus news, Director Gary J. Pruden sold 12,530 shares of the company’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the transaction, the director now owns 11,978 shares in the company, valued at $1,138,389.12. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $123.15, for a total transaction of $41,994.15. Following the transaction, the chief accounting officer now owns 62,216 shares of the company’s stock, valued at $7,661,900.40. The disclosure for this sale can be found here. Insiders sold 40,852 shares of company stock valued at $3,922,001 in the last three months. Corporate insiders own 1.50% of the company’s stock.

Lantheus Price Performance

Shares of LNTH opened at $107.36 on Friday. The firm has a market cap of $7.44 billion, a PE ratio of 16.39 and a beta of 0.50. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. The business’s 50 day moving average price is $104.45 and its two-hundred day moving average price is $85.69.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company had revenue of $394.10 million for the quarter, compared to the consensus estimate of $382.12 million. During the same period in the prior year, the company earned $1.40 earnings per share. The firm’s revenue was up 22.5% compared to the same quarter last year. On average, equities analysts anticipate that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.